Please login to the form below

Juno Therapeutics

This page shows the latest Juno Therapeutics news and features for those working in and with pharma, biotech and healthcare.

BMS and 2seventy bio move away from CAR-T programme

This cancellation is the second anti-BCMA CAR-T programme to be halted under BMS in the last twelve months, after a development programme with Juno Therapeutics was scrapped in February

Latest news

FDA begins speedy review of BMS’ CAR-T liso-cel

The lawsuit argued that Gilead subsidiary Kite Therapeutics infringed on a patent licensed by BMS’ Juno Therapeutics from Sloan Kettering and Memorial Sloan Kettering Cancer Centre for exclusive rights to its ... However, on that front there are a
Gilead owes BMS millions after losing Yescarta patent infringement trial

The basis of the lawsuit is that Yescarta, which is marketed by Gilead’s Kite Pharma division, infringed on a patent licensed by BMS’ Juno Therapeutics from Sloan Kettering and the ... Given that Kite independently developed Yescarta and assumed all
Celgene boosts IO presence with Immatics deal

It also acquired CAR-T specialist Juno therapeutics for $9bn in 2018, giving it rights to lead CAR-T candidate JCAR017 (lisocabtagene maraleucel).
The year of the blockbuster

These include Juno Therapeutics’ CAR T-cell therapy, lisocabtagene maraleucel, for diffuse large B-cell lymphoma, and Alexion’s next-generation Soliris treatment, ravulizumab, for paroxysmal nocturnal haemoglobinuria.
Bluebird and Celgene BCMA CAR-T kicks off ASCO

s lymphoma developed by Juno Therapeutics, which was acquired by Celgene earlier this year. ... That includes data on Jounce Therapeutics’ ICOS-targeting antibody JTX-2011 which disappointed investors when the ASCO abstract was made public earlier this

More from news
Approximately 7 fully matching, plus 19 partially matching documents found.

Latest Intelligence

Sourcing R&D innovation: why pharma companies need to evolve their business models

and. CAR-T therapies. Gilead’s acquisition of Kite Pharma and Bristol-Myers Squibb’s acquisition of Juno Therapeutics, as well as the merger and acquisition agreements between Novartis/Spark and
The European Medicines Agency: PRIME’d for access?

sales, and 6 are in the top 10 companies with Pfizer (with Spark Therapeutics), Novartis (by acquiring AveXis), Celgene (with Bluebird and through acquiring Juno Therapeutics), Sanofi, Roche and Merck all ... Those prices pale in comparison though when
Deal Watch January 2018

Impact Biomedicines for a potential $7bn in early January and then it scooped up the remaining 90% of its CAR-T and TCR technology partner Juno Therapeutics for $9bn. ... Juno Therapeutics/ Celgene. CAR-T and TCR therapeutics portfolio incl JCAR017
Deal Watch November 2016

One piece of unwelcome news this month was from Juno Therapeutics, which announced it had halted a phase 2 trial of JCAR015, its CAR T cell immunotherapeutic, in patients with relapsed ... This is despite some positive news for Juno released at the
Pharma deals in July 2015

It still sounds like a high price but perhaps it is in Celgene'sDNA because only a month ago it bought shares in Juno Therapeutics at over a 100% premium in

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

PureTech Health appoints new chief financial officer

Muijrers has worked with pharmaceutical clients such as Kite Pharma, Ablynx and Juno Therapeutics, and said: “I am thrilled to join PureTech Health, one of the most exiciting and unique biopharma
Juno Therapeutics names Cindy Elkins as CIO

Cindy Elkins has joined Juno Therapeutics - now a part of Celgene - as its new chief information officer, a role that will see her report directly to Hans Bishop, Juno’s president ... She said: “I am delighted to join Juno, a company that reflects my